Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Huntingdon shares dive on fewer orders

Tuesday 01 July 1997 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

The share price of Huntingdon Life Sciences, the controversial group which tests drugs on animals, dived by 15 per cent to 55.5p after the company warned that disappointing new orders would leave profits for the year to December "substantially below" last year's pounds 9.4m, writes Sameena Ahmad.

Christopher Cliffe, chief executive, said that recent allegations from animal rights groups which had led to criminal proceedings against several employees and a Home Office investigation into the group's working practices had proved seriously disruptive: "Considerable management effort has been devoted to keeping clients informed and to retaining clients' confidence," he said.

Glaxo Wellcome and Zeneca have recently stopped awarding new drug testing contracts to Huntingdon pending an investigation into a disturbing TV documentary which showed scenes of cruelty to animals at its Cambridgeshire laboratory. SmithKline Beecham and Zeneca are awaiting the Home Office report.

Shares in the company fell from 121p following the programme. Huntingdon said yesterday that recent monthly new orders of pounds m-pounds 5m were below expectations and that marketing programmes to increase new orders had been "negatively impacted by the allegations".

Mr Cliffe said Huntingdon would incur a small loss in the first half after providing pounds 1m for additional costs relating to allegations. He expected the group to return to profit in 1997.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in